Horst Lindhofer

4.5k total citations · 1 hit paper
95 papers, 3.5k citations indexed

About

Horst Lindhofer is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, Horst Lindhofer has authored 95 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Radiology, Nuclear Medicine and Imaging, 45 papers in Oncology and 34 papers in Immunology. Recurrent topics in Horst Lindhofer's work include Monoclonal and Polyclonal Antibodies Research (54 papers), Immunotherapy and Immune Responses (31 papers) and CAR-T cell therapy research (28 papers). Horst Lindhofer is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (54 papers), Immunotherapy and Immune Responses (31 papers) and CAR-T cell therapy research (28 papers). Horst Lindhofer collaborates with scholars based in Germany, United Kingdom and Switzerland. Horst Lindhofer's co-authors include Peter Ruf, Carsten Bokemeyer, Diane Seimetz, Michael Jäger, M. M. Heiss, Ralph Mocikat, Alexander Burges, Pauline Wimberger, S. Thierfelder and A. Schoberth and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Horst Lindhofer

94 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

2010 405 citations M. M. Heiss, Pauline Wimberger et al. International Journal of Cancer profile →

Peers

Countries citing papers authored by Horst Lindhofer

Since Specialization

Citations

This map shows the geographic impact of Horst Lindhofer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Horst Lindhofer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Horst Lindhofer more than expected).

Fields of papers citing papers by Horst Lindhofer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Horst Lindhofer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Horst Lindhofer. The network helps show where Horst Lindhofer may publish in the future.

Co-authorship network of co-authors of Horst Lindhofer

This figure shows the co-authorship network connecting the top 25 collaborators of Horst Lindhofer. A scholar is included among the top collaborators of Horst Lindhofer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Horst Lindhofer. Horst Lindhofer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	2010P Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): Interim analysis of a phase I study 2024 ·Annals of Oncology ·Artur A. Antoniewicz, (unknown), Frederik Wessels, M. Lenhart, Manuel Neuberger, Peter Ruf, Horst Lindhofer, R. Oberneder, Maximilian C. Kriegmair	3
2	Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model 2023 ·Frontiers in Immunology ·(unknown), (unknown), (unknown), (unknown), Anika Klaus, (unknown), Peter Ruf, Horst Lindhofer, Holger N. Lode, (unknown), Johannes H. Schulte, Angelika Eggert, Patrick Hundsdoerfer, Annette Künkele, (unknown)	7
3	First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity 2021 ·Cancer Immunology Immunotherapy ·Peter Ruf, H Bauer, A. Schoberth, (unknown), Horst Lindhofer	16
4	Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer 2018 ·British Journal of Cancer ·Maren Knödler, (unknown), Volker Kunzmann, Jörg Trojan, S Daum, Michael Schenk, Frank Kullmann, (unknown), Dirk Behringer, Michael Stahl, Salah‐Eddin Al‐Batran, Ulrich Hacker, Stefan Ibach, Horst Lindhofer, Florian Lordick	66
5	Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery 2015 ·Molecular Cancer Therapeutics ·(unknown), Peter Ruf, Nina Eißler, Frauke Neff, Raymund Buhmann, Horst Lindhofer, Ralph Mocikat	13
6	Expression of Epithelial Cell Adhesion Molecule in Paired Tumor Samples of Patients With Primary and Recurrent Serous Ovarian Cancer 2013 ·International Journal of Gynecological Cancer ·Klaus Pietzner, Hannah Woopen, (unknown), J. M. Thomas, Elena Ioana Braicu, (unknown), (unknown), (unknown), Carsten Denkert, Horst Lindhofer, (unknown), Jalid Sehouli	14
7	Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor Immunotherapy 2013 ·Molecular Medicine ·Nina Eißler, Josef Mysliwietz, (unknown), Peter Ruf, Horst Lindhofer, Ralph Mocikat	8
8	三官能性抗体Catumaxomab(抗EpCAM×Anti-CD3)による治療を受けた悪性腹水患者の第2/3相試験に関する免疫モニタリング結果 2012 ·Cancer Research ·(unknown), (unknown), (unknown), Juergen Heß, (unknown), (unknown), Pauline Wimberger, (unknown), (unknown), (unknown), Horst Lindhofer	1
9	Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients 2010 ·British Journal of Clinical Pharmacology ·Peter Ruf, Michael Kluge, Michael Jäger, Alexander Burges, Constantin Volovăț, M. M. Heiss, Jürgen Hess, Pauline Wimberger, (unknown), Horst Lindhofer	65
10	Structural and functional characterization of the trifunctional antibody catumaxomab 2010 ·mAbs ·Dirk Chelius, Peter Ruf, Patrick Gruber, Matthias Plöscher, Reinhard Liedtke, (unknown), Juergen Heß, (unknown), Horst Lindhofer	112
11	Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy 2010 ·Cancer Treatment Reviews ·Diane Seimetz, Horst Lindhofer, Carsten Bokemeyer	211
12	Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis 2009 ·Journal of Experimental & Clinical Cancer Research ·Michael A. Ströhlein, Robert Siegel, Michael Jäger, Horst Lindhofer, Karl‐Walter Jauch, M. M. Heiss	34
13	Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3) 2009 ·Journal of Immunotherapy ·Martin Sebastian, Philipp Kiewe, Wolfgang Schuette, (unknown), Christian Peschel, Folker Schneller, Karl-Heinz Rühle, Georg Nilius, Ralf Ewert, (unknown), Bernward Passlick, Wulf Sienel, Rainer Wiewrodt, Michael Jäger, Horst Lindhofer, (unknown), Alexander Schmittel	44
14	EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges 2007 ·British Journal of Cancer ·(unknown), (unknown), Peter Ruf, Horst Lindhofer, Marc C. Winslet	76
15	Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer 2006 ·Clinical Cancer Research ·Philipp Kiewe, Stephan Hasmüller, Steffen Kahlert, (unknown), Brigitte Rack, Alexander Marmé, Agnieszka Korfel, Michael Jäger, Horst Lindhofer, Harald Sommer, Eckhard Thiel, Michael Untch	139
16	Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma 2006 ·Annals of Oncology ·Philipp Kiewe, (unknown), Alexander Schmittel, Peter Ruf, Horst Lindhofer, E. Thiel, Dirk Nagorsen	5
17	The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells 2000 ·British Journal of Cancer ·Reinhard Zeidler, Josef Mysliwietz, (unknown), (unknown), Irmgard Ziegler, Bärbel Schmitt, Barbara Wollenberg, Horst Lindhofer	148
18	Gene therapy of B-cell lymphoma with cytokine gene-modified trioma cells 1999 ·International Journal of Cancer ·John Strehl, (unknown), (unknown), (unknown), Horst Lindhofer, Ralph Mocikat	16
19	In VivoProcessing of Pr160 from Human Immunodeficiency Virus Type 1 (HIV) in Acutely Infected, Cultured Human T-Lymphocytes 1995 ·Virology ·Horst Lindhofer, K. von der Helm, Hans Nitschko	31
20	Effect of fish oil concentrate on the lipoprotein profile in patients suffering from type II diabetes mellitus 1992 ·Medizinische Klinik - Intensivmedizin und Notfallmedizin ·Wolfram Herrmann, Julia Biermann, (unknown), Horst Lindhofer	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact